Disclosures for "Early Relapse Risk in Biopsy-confirmed Primary CNS Vasculitis: A Cohort Study"
-
Dr. Nguyen has nothing to disclose.
-
Dr. Bilodeau has nothing to disclose.
-
Dr. Mahler has received research support from The Sumaira Foundation.
-
Ms. Drosu has nothing to disclose.
-
Dr. Bobrowski-Khoury has nothing to disclose.
-
Dr. Quinn has nothing to disclose.
-
Dr. Mikami has nothing to disclose.
-
Dr. Anderson has nothing to disclose.
-
Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Pharma. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Levy has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Various law firms. The institution of Dr. Levy has received research support from National Institutes Health.